Core Points - Addex Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - The 2025 Annual General Meeting (AGM) is scheduled for June 24, 2025, at 11:00 am CEST in Geneva, Switzerland [1] Agenda Items - Approval of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements for the business year 2024 [2] - Consultative vote on the Compensation Report for the business year 2024 [3] - Re-elections of the Board of Directors, including Vincent Lawton as Chairman [3] - Approval of compensation for the Board of Directors and Executive Management [3] Company Overview - Addex holds a 20% equity interest in Neurosterix LLC, which is advancing allosteric modulator programs for various neurological conditions [4] - The company is also developing a GABAB PAM drug candidate in partnership with Indivior for substance use disorders [4] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [4]
Addex Convenes Annual General Meeting 2025